Back to top
more

Esperion Therapeutics (ESPR)

(Delayed Data from NSDQ)

$2.12 USD

2.12
6,292,577

+0.12 (6.00%)

Updated Nov 5, 2024 03:59 PM ET

After-Market: $2.11 -0.01 (-0.47%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Aquestive Therapeutics (AQST) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -8.33% and 6.68%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Esperion Therapeutics (ESPR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Esperion Therapeutics (ESPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Is Esperion Therapeutics (ESPR) Down 3.9% Since Last Earnings Report?

by Zacks Equity Research

Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Esperion's (ESPR) Q2 Loss Narrows, Revenues Soar Year Over Year

by Zacks Equity Research

Esperion (ESPR) reports a narrower-than-expected loss for the second quarter of 2024. Revenues beat estimates. Sales rise year over year owing to higher collaboration revenues.

Esperion Therapeutics (ESPR) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of 66.67% and 42.27%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Amneal Pharmaceuticals (AMRX) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Amneal (AMRX) delivered earnings and revenue surprises of 14.29% and 6.75%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Verve Therapeutics (VERV) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Verve Therapeutics (VERV) delivered earnings and revenue surprises of 13.24% and 27.26%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Assertio (ASRT) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Assertio (ASRT) delivered earnings and revenue surprises of -100% and 2.51%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Strength in Kidney Care Likely to Aid DaVita's (DVA) Q2 Earnings

by Zacks Equity Research

Improvement in RPT and cost-saving initiatives are likely to have boosted DaVita's (DVA) top line in the second quarter.

Esperion Therapeutics (ESPR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Esperion Therapeutics (ESPR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Product Demand Likely to Aid Organon's (OGN) Q2 Earnings

by Zacks Equity Research

Continued solid uptake of Organon's (OGN) products is expected to have driven second-quarter revenues.

Viatris (VTRS) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Viatris' (VTRS) Q2 results are likely to gain from growth in Emerging Markets and Europe and expansion of business activities in Japan, offset by declines in North America.

Corcept Therapeutics (CORT) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Corcept (CORT) delivered earnings and revenue surprises of 39.13% and 6.41%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Strength Seen in Aurinia (AUPH): Can Its 5.6% Jump Turn into More Strength?

by Zacks Equity Research

Aurinia (AUPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Why Is Catalyst (CPRX) Up 0.7% Since Last Earnings Report?

by Zacks Equity Research

Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Esperion Therapeutics (ESPR) Up 14.2% Since Last Earnings Report?

by Zacks Equity Research

Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Esperion's (ESPR) Drugs Get EU Nod for Lowering Heart Risk

by Zacks Equity Research

Esperion's (ESPR) Nilemdo & Nustendi get the European Commission's nod for label expansion based on data from the CLEAR Outcomes study.

Esperion (ESPR) Q1 Earnings Beat, Stock Up on Strong Revenues

by Zacks Equity Research

Esperion's (ESPR) first-quarter earnings and sales beat estimates on the back of better-than-expected collaboration revenues.

Esperion Therapeutics (ESPR) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of 525% and 159.32%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

by Zacks Equity Research

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Why Is Esperion Therapeutics (ESPR) Up 2% Since Last Earnings Report?

by Zacks Equity Research

Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Industry Outlook Highlights United Therapeutics, Esperion Therapeutics., Heron Therapeutics, Lyra Therapeutics and Aldeyra Therapeutics

by Zacks Equity Research

United Therapeutics, Esperion Therapeutics., Heron Therapeutics, Lyra Therapeutics and Aldeyra Therapeutics are part of the Zacks Industry Outlook article.

Kinjel Shah headshot

5 Small Drug Stocks to Buy From a Rebounding Industry

by Kinjel Shah

Innovation is expected to continue to drive growth of the Medical-Drugs industry. UTHR, ESPR, HRTX, LYRA and ALDX may prove to be good additions to one's portfolio.

Esperion (ESPR) Q4 Earnings Top, Stock Up on Strong Revenues

by Zacks Equity Research

Esperion's (ESPR) fourth-quarter earnings and sales beat estimates on the back of better-than-expected collaboration revenues.